Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Clin Endosc > Volume 52(2); 2019 > Article
Review Fecal Microbiota Transplantation: An Update on Clinical Practice
Kyeong Ok Kim1,2, Michael Gluck2,orcid
Clinical Endoscopy 2019;52(2):137-143.
DOI: https://doi.org/10.5946/ce.2019.009
Published online: March 26, 2019

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea

2Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA

Correspondence: Michael Gluck Digestive Disease Institute, Virginia Mason Medical Center, 1100 Ninth Ave, C3-GAS, Seattle, WA 98101, USA Tel: +1-206-223-2319, Fax: +1-206-341-1405, E-mail: Michael.Gluck@virginiamason.org
• Received: December 8, 2018   • Revised: January 10, 2019   • Accepted: March 6, 2019

Copyright © 2019 Korean Society of Gastrointestinal Endoscopy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 14,954 Views
  • 521 Download
  • 126 Web of Science
  • 132 Crossref
  • 148 Scopus
prev next
Full Article

Download PDF Download PDF

  • Fecal microbiota transplantation (FMT) is an infusion in the colon, or the delivery through the upper gastrointestinal tract, of stool from a healthy donor to a recipient with a disease believed to be related to an unhealthy gut microbiome. FMT has been successfully used to treat recurrent Clostridium difficile infection (rCDI). The short-term success of FMT in rCDI has led to investigations of its application to other gastrointestinal disorders and extra-intestinal diseases with presumed gut dysbiosis. Despite the promising results of FMT in these conditions, several barriers remain, including determining the characteristics of a healthy microbiome, ensuring the safety of the recipient with respect to long-term outcomes, adequate monitoring of the recipient of fecal material, achieving high-quality control, and maintaining reasonable costs. For these reasons, establishing uniform protocols for stool preparation, finding the best modes of FMT administration, maintaining large databases of donors and recipients, and assuring that oral ingestion is equivalent to the more widely accepted colonoscopic infusion are issues that need to be addressed.
  • Keywords: Fecal microbiota transplantation; Clostridium difficile infection; Colonoscopy
Since the first modern descriptions of its use in 1958 [1], fecal microbiota transplantation (FMT) has increasingly gained interest and rapid acceptance during the last 10 years [2]. FMT is defined as the infusion of stool from a healthy individual to a patient with presumed gut dysbiosis [3,4]. FMT can also be delivered through an enteral route either via an endoscope, a nasoenteric tube, or capsules for ingestion. The presumed mechanism of action appears to be the establishment of a new gut microbiota community to restore the normal gut function [5-7]. On the basis of the concept of repopulating the gut with a healthy microbiome, FMT has been successfully used in the treatment of Clostridium difficile infection (CDI), and recommended for other conditions such as inflammatory bowel disease (IBD), autoimmune disorders, certain allergic diseases, and metabolic disorders such as obesity [8]. In recurrent CDI (rCDI), the efficacy and safety of FMT has been proven by several randomized clinical trials (RCTs), and guidelines recommend the use of FMT as a second-line treatment [9-15]. Success rates approaching 92% have been demonstrated in the treatment of rCDI [10,11].
With the increasing use of FMT owing to its success in treating various diseases, there is growing demand for standardizing the preparation of fecal material, using accepted standards for the delivery, ensuring safety for the recipient, monitoring long-term outcomes, and continuously improving the procedural processes and safety.
The use of FMT became rapidly accepted mainly owing to its success in treating rCDI. Data from several RCTs and a large case series revealed the efficacy and safety of FMT [9-12]. A recent systematic review and meta-analysis of 7 RCTs and 30 case series demonstrated the superiority of FMT over vancomycin therapy, with resolution rates as high as 92% [16]. Moayyedi et al. showed that FMT was superior to placebo or vancomycin therapy [17]. Fischer et al. reported that FMT clinically cured 91% of patients with severe rCDI that failed maximal medical therapy [18].
The indications for FMT include mild to moderate rCDI after a second recurrence following treatment with a standard antibiotic, moderate rCDI that is not responding to standard therapy after 1 week, and severe CDI that is refractory to standard therapy after 48 h [3,19]. The recent U.S. guidelines recommend FMT in patients with 3 or more recurrences of CDI, although most clinicians prescribe FMT if CDI recurs after 2 courses of antibiotics [15]. The European consensus guidelines suggest that FMT should be considered after the first episode if the disease is severe and refractory to the initial antibiotic therapy [20]. Although there are no strict guideline recommendations stating that CDI should be initially treated with FMT instead of antibiotics, there may be special situations that would justify its application, such as inability to deliver antibiotics to a patient with severe disease, intolerance of the patient to antibiotics, or as a substitute for surgery in highly unstable patients [21].
It has been suggested that gut dysbiosis underlies the pathogenesis of IBD. Zhang et al. [22] reported that in ulcerative colitis, there is decreased diversity in the patient’s microbiota with fewer Firmicutes bacteria and more Proteobacteria. In a recently reported RCT on ulcerative colitis, the response rate to FMT was 55%, with remission in 20% of the patients [23]. Another RCT reported similar response and remission rates of 54% and 27%, respectively [24]. A meta-analysis of 4 RCTs in patients with ulcerative colitis demonstrated a 28% remission rate in patients treated with FMT compared with 8% in those who received placebo [23]. FMT appears to have lower efficacy for IBD than for rCDI, suggesting that other factors are associated with IBD flares besides gut dysbiosis [25].
Several reports have implied that IBD flares were induced by FMT that was administered for CDI [2,26,27]. A careful follow-up of patients with IBD treated with FMT is warranted because of this concern. An American Gastroenterology Association expert review, however, suggested that earlier FMT in patients with IBD and CDI might be recommendable owing to the relevant complication rate of CDI in these patients [28]. Several RCTs in patients with Crohn’s disease are currently under way. To date, there are no standardized practice guidelines for the use of FMT in IBD.
Besides rCDI and IBD, FMT is also being evaluated and considered an experimental treatment for other diseases including irritable bowel syndrome (IBS) [29], nonalcoholic steatohepatitis [30], hepatic encephalopathy [31], obesity [32], and neurological diseases [33,34].
Although donor screening is well accepted, recipient screening is controversial and without a consensus. Performing viral hepatitis, human immunodeficiency virus, and syphilis tests is recommended before FMT, so that if these diseases were to occur after FMT, clinicians would know that the disease was not transmitted from the donor to the recipient [21]. Kelly et al., in a large case series drawn from multiple centers in the United States, showed that FMT seemed safe in immunocompromised patients, with the exception of neutropenic patients as a standard precaution [34].
To minimize the risk of infection or other disease transmission, potential donors undergo rigorous screening including thorough history taking, serological tests, and fecal tests for parasitic, virologic, and bacterial pathogens [35]. Although there are some variations between institutions, there are existing accepted protocols for donor screening (Tables 1, 2) [3,36,37].
Donor stool is provided from 2 sources: patient-directed donors and universal donors through stool banks [38,39]. Patient-directed donors are identified by the recipients, usually family members including spouses, siblings, children, or friends. Patient-directed donors are becoming less frequently used unless the recipient prefers a donor whose diet and other features are known, or if the recipient is concerned about transmissible agents that are perceived to exist in universal donors. The use of patient-directed donor stool incurs treatment delays owing to the time required for sourcing, screening, and testing donors, with resultant increased costs and scheduling problems [39,40]. Additionally, using patient-directed donors may result in the donor feeling coerced and at a risk of revealing confidential information [41].
Using universal donors for FMT has emerged as the most utilized method in the United States. Healthy volunteers who have a young age and a normal body mass index provide the stool after undergoing thorough history taking, physical examination, and serum and fecal pathogen screening tests [42].
The use of universal donors has enabled a number of advances in FMT. Decreased microbial diversity is considered a possible cause of rCDI and other diseases of an altered microbiome. Using fecal material from multiple healthy donors could theoretically enhance the therapeutic efficacy of an infusion or ingestion. An RCT on the application of FMT with multiple donors in ulcerative colitis showed clinical remission and endoscopic improvement as well as greater microbial diversity in the recepients [24]. More studies are needed to confirm the value of multidonor FMT.
In addition, Lee et al. [43] conducted a noninferiority RCT of FMT with frozen and thawed stool in comparison with fresh stool for rCDI, to ensure the viability of microbes after freezing. They reported clinical resolution rates of 83.5% and 85.1% in each group, showing that frozen fecal material was as efficacious as fresh stool. Using frozen stool from universal donors reduces recipient costs as well as the time between the decision to perform FMT and the actual infusion [39,40].
Owing to the cost-effectiveness and convenience of use of fecal material from universal donors, stool banks such as OpenBiome have emerged. OpenBiome uses strict protocols for the recruitment of healthy volunteers: the volunteers are screened, standardized products are generated, and the products are stored after freezing and can be delivered rapidly to 99% of the entire United States [42]. The additional advantages of stool banks are the ability to track registries and perform research on larger data obtained from multiple sites that conduct FMT, with the goal of assuring safety and efficacy [44]. The U.S. Food and Drug Administration (FDA) has approved stool banks such as OpenBiome to provide fecal material for FMT for the treatment of rCDI [45]. For indications other than rCDI, the FDA requires an investigational drug application [46].
One of the main concerns about the use of stool banks is that multiple recipients could be adversely affected by a currently undetectable infection or transmissible process. Open-Biome has used extremely strict and detailed questionnaires to identify possibly risky donors in advance, and also to rescreen volunteers 60 days after the submission and before the release of the stool. Samples are also stored for future tracking [42].
Although there are trivial differences depending on the individual situation, most institutes prepare the stool based on the same protocol. The donor provides fresh stool within 1 month after screening [3]. The potential donors collect their stool into a clean plastic bag and bring it to the microbiology laboratory. A minimum of 50 g of stool is needed [47]. Then, the stool is diluted in normal saline, mixed in a sterile bag by hand stirring, and shaken or blenderized. It is then filtered through moistened 5-layer sterile gauze in a funnel and stored in a restricted safety cabinet to be delivered within 4 h of presentation to the endoscopy suite.
In the case of FMT with a universal donor, the fecal material is processed to 250-mL aliquots in a similar standardized method and stored at −80°C until delivered on dry ice to each requesting institute [42].
Fecal microbiota capsules could be prepared by concentration of the diluted, blended slurry, processed similarly. Then, the fecal solution is pipetted into a capsule holding 650 mL and then sealed into a second capsule. Commercially available acid-resistant, hypromellose capsules (DRcapsTM; Capsugel, Cambridge, MA, USA) are usually utilized. A total of 30 capsules are prepared as a single therapeutic dose from each donor stool [48]. Capsules are also stored at −80°C (−112°F) before use, maximally up to 6 months.
It seems that FMT for rCDI is most efficacious in patients with mild to moderate disease that responded to antibiotics against C. difficile by the fourth day [11]. In the other patients, the concern is that the diarrhea may be from another source. Some clinicians have recommended the earlier use of FMT for patients with severe or severe-complicated disease, as failure of standard therapy could result in higher morbidity and mortality [49]. An accepted method of FMT is to provide antibiotics for at least 3 days before infusion to reduce the amount of C. difficile [20]. Antibiotics are generally discontinued at 24–48 h before the FMT.
If the FMT is delivered by colonoscopy, bowel preparation is recommended to improve the visualization of the colon. In patients with a severe ileus, bowel preparation can be replaced by enemas or can be omitted [38]. The standard dose of FMT is specific to each institution or physician; however, about 50–100 g of donor fecal material that has been diluted to 250–500 mL of infusate is most commonly used [9,12,43,48].
FMT can be administered either directly to the colon or from the upper gastrointestinal tract through capsule ingestion [38]. Delivery to the colon is generally performed using colonoscopy, and less frequently through flexible sigmoidoscopy or an enema. Colonoscopic delivery has an efficacy of 84%–93% [41] and is the modality of choice according to published studies [47,50,51]. If right-sided delivery of FMT is achieved using colonoscopy, the cure rate on a single infusion is 93% [9]. The most serious risk that has been reported with respect to lower gastrointestinal tract administration is perforation [39,52]. Theoretically, bleeding, adverse reaction to sedative drugs, cardiovascular events, transient fevers, or infections could occur, as with any colonoscopy procedure.
For patients with ileus, severe colitis, or objection to colonoscopy, FMT can be provided through the upper gastrointestinal tract via nasoenteric tubes, esophagogastroduodenoscopy, or capsule ingestion [38]. The efficacy rates were reported to be between 81% and 86% [41]. All forms of upper tract delivery increase the risk of vomiting or aspiration [53]. Capsule delivery is the most recent modality of FMT. Capsules seem to be a reasonable choice for patients who have contraindications to colonoscopy, are geographically distant from an institution that performs colonoscopy, and are opposed to lower gastrointestinal tract access. Capsule delivery reduces the procedure time, colonoscopy cost, need for colon preparation, and risk of colonoscopy complications [54]. Kao et al. demonstrated a comparable efficacy of capsule-delivered FMT to that of colonoscopy-delivered FMT [55]. Although the standard dose per capsule is not yet defined, several studies have shown that a mean 1.6 g of stool per capsule yields a 70% cure rate without adverse events [48,56]. Although no consensus has been achieved, the common impression by a number of authors is that colonoscopic administration has an about 5%–10% higher cure rate in rCDI [47,50,51], with the additional advantage of assuring that the fecal material reaches the colon because a water jet can be used to spray the material directly onto the mucosa [21]. Table 3 summarizes the strengths and weakness of each modality.
The 2 most common side effects of FMT are bloating and loose stools for the first 24 h, which usually resolve soon thereafter [35]. Most patients generally have formed stool by 1–2 weeks. Stool testing for resolution is not recommended in those with formed stool, but is considered if 3 or more diarrhea stools per day occur after a few weeks [15,38]. The polymerase chain reaction test for C. difficile toxin may remain positive for 30 days after a successful treatment, which is another reason not to test asymptomatic FMT recipients [38]. A confusing situation is when abdominal cramping and intermittent frequent bowel movements occur in a patient who might be a carrier of C. difficile and who has received an FMT. Such patients most likely have post-infectious IBS. Therefore, the clinician should ideally be able to distinguish post-infectious IBS from rCDI to avoid unnecessarily repeating the FMT.
To date, there is no accepted standard protocol for follow-up. Most physicians and clinic staff contact the patient to assess treatment success and complications about 3–7 days after FMT. Another follow-up contact at 4–8 weeks is recommended [38].
If the patient develops liquid stool and recurrence of symptoms with a positive stool test for C. difficile, the FMT is considered a failure [13]. A recent study suggested that most failures occur within 4 weeks [49]. Allegretti et al. [57] reported that of the failed therapy cases, 25% failed within the first week and the patients are described as primary nonresponders. Another 61% failed between weeks 1 and 4, with the patients referred to as early secondary nonresponders. The rest were considered late secondary nonresponders. On the basis of these data, the authors suggested follow-up of patients approximately 4 weeks after the FMT [57].
Much of the concern about FMT arises from the fact that the long-term risks are unknown. Screening of donors by means of a thorough history taking may not reveal all future risks. Most FMT protocols endeavor to exclude donors with metabolic syndrome, obesity, neuropsychiatric disorders, and malignancies; however, a disease might emerge in the donor at a later date. This represents both a concern about FMT and a justification for the existence of stool banks, as follow-up of donors and maintenance of records would be more likely in stool banks, allowing the earlier identification of risks.
FMT is an established treatment for rCDI, and is considered a second-line treatment. It is also being considered for other gastrointestinal diseases such as IBD, IBS, hepatic steatosis, and hepatic encephalopathy. Other disorders that may be related to gut dysbiosis, such as obesity, metabolic syndrome, autoimmune disorders, and neurological diseases, may also be improved by FMT. With stool banks providing universal door fecal material that has been highly screened and catalogued, barriers such as cost and availability can be overcome, allowing research and treatment to be simplified. Additionally, with the advent of capsule FMT, further increases in the use of this treatment may emerge with improved convenience, reduced patient reluctance, and simplified procedural preparation. To maintain patient safety and appropriate use of FMT, standardized protocols for donor screening, stool preparation, methods of delivery, and recipient indications for treatment are expected to emerge.
Table 1.
Suggested Exclusion Criteria for Potential Stool Donors with a Risk of Infection or Microbiome-Associated Disease
Exclusion criteriaa)
Age <18 yr or >65 yr
BMI >30 kg/m2
Metabolic syndrome
Moderate to severe undernutrition
History of antibiotics use in the last 6 mo
Diarrhea within the last 3–6 mo
History of Clostridium difficile colitis
Immune disorder or use of immunosuppressive medications
History of drug use or other recent risk factor for HIV or viral hepatitis
History of travel to a tropical region in last 3 mo
Any gastrointestinal illness (IBD, IBS, gastrointestinal malignancy, or major surgery) or complaints
History of autoimmune or atopic illness
History of chronic pain syndrome (fibromyalgia, chronic fatigue syndrome)
Neurologic or neurodevelopmental disorders
History of malignancy

HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome.

a)Each institution can adopt different criteria.

Table 2.
Suggested Laboratory Tests for Potential Donors of Fecal Microbiota Transplantationa)
Tests Blood Stool
Bacteria Treponema Enteric pathogen culture: Salmonella, Shigella, Campylobacter
Helicobacter pylori EIAb)
VRE
Viruses Hepatitis A virus IgM Norovirus EIA or PCR
Hepatitis surface antigen Rotavirus EIA
Anti-hepatitis C virus
HIV 1 and 2
Parasites Entamoeba histolytica Ovum and parasite
Strongyloides stercoralis Microsporidia
Giardia fecal antigen/EIA
Cryptosporidium EIA
AFB for Isospora and Cyclospora
Others Complete blood count Clostridium difficile test
Liver function test Toxin PCR
ESR and CRP

AFB, acid-fast bacilli; CRP, C-reactive protein; EIA, enzyme immunoassay; ESR, erythrocyte sedimentation rate; HIV, human immunodeficiency virus; IgM, immunoglobulin M; PCR, polymerase chain reaction; VRE, vancomycin-resistant Enterococcus.

a)The blood and stool tests should be completed within 1 month of donation, and the tests could be adopted differently depending on each institution and circumstance.

b)The test for Helicobacter pylori is usually needed in the case of upper gastrointestinal delivery.

Table 3.
Analysis of Administration Modalities for Fecal Microbiota Transplantation
Modality Strength Weakness
Nasoenteric tube 1. No necessity for sedation 1. Discomfort associated with the administration
2. Low cost 2. Necessity for radiologic confirmation
3. Risk of vomiting and aspiration
Upper endoscopy 1. Safely performed in patients with a high risk for colonoscopy complications 1. Same weaknesses as those of nasoenteric tube
2. Procedure-related risk
3. Necessity for sedation
Capsule 1. Noninvasive 1. Large burden of the capsule
2. More aesthetic appeal 2. Risk of vomiting and aspiration
3. Cost- and time saving 3. Cost
4. Convenience of administration
Colonoscopy 1. Strong evidence of efficacy for rCDI 1. Procedure-related risk
2. Useful for differential diagnosis 2. Necessity for sedation
3. Necessity for technical expertise
4. Additional cost
Sigmoidoscopy 1. Can be preferred by patients 1. Procedure-related risk
2. Inability to reach the right-sided colon
Retention enema 1. Low cost 1. Difficult to retain in some cases
2. Well tolerated 2. Inability to reach the right-sided colon
3. No need for sedation and can be preferred by patients 3. Modality with the lowest efficacy
4. Can be easily repeated

rCDI, recurrent Clostridium difficile infection.

  • 1. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44:854–859.PubMed
  • 2. Chin SM, Sauk J, Mahabamunuge J, Kaplan JL, Hohmann EL, Khalili H. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease: a single-center experience. Clin Gastroenterol Hepatol 2017;15:597–599.ArticlePubMedPMC
  • 3. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9:1044–1049.ArticlePubMedPMC
  • 4. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 2013;78:240–249.ArticlePubMed
  • 5. Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis 2005;40:1598–1600.ArticlePubMedPDF
  • 6. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22:813–818.ArticlePubMedPDF
  • 7. Sadowsky MJ, Khoruts A. Faecal microbiota transplantation is promising but not a panacea. Nat Microbiol 2016;1:16015.ArticlePubMedPDF
  • 8. Choi HH, Cho YS. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin Endosc 2016;49:257–265.ArticlePubMedPMCPDF
  • 9. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014;48:693–702.ArticlePubMed
  • 10. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 2016;165:609–616.ArticlePubMedPMC
  • 11. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407–415.ArticlePubMed
  • 12. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014;58:1515–1522.ArticlePubMedPMC
  • 13. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478–498; quiz 499.ArticlePubMedPDF
  • 14. Trubiano JA, Cheng AC, Korman TM, et al. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J 2016;46:479–493.ArticlePubMed
  • 15. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:987–994.ArticlePubMedPDF
  • 16. Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 2017;46:479–493.ArticlePubMed
  • 17. Moayyedi P, Yuan Y, Baharith H, Ford AC. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust 2017;207:166–172.ArticlePubMed
  • 18. Fischer M, Sipe B, Cheng YW, et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 2017;8:289–302.ArticlePubMedPMC
  • 19. Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 2015;149:223–237.ArticlePubMedPMC
  • 20. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017;66:569–580.ArticlePubMedPMC
  • 21. Vindigni SM, Surawicz CM. Fecal microbiota transplantation. Gastroenterol Clin North Am 2017;46:171–185.ArticlePubMed
  • 22. Zhang SL, Wang SN, Miao CY. Influence of microbiota on intestinal immune system in ulcerative colitis and its intervention. Front Immunol 2017;8:1674.ArticlePubMedPMC
  • 23. Costello SP, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther 2017;46:213–224.ArticlePubMed
  • 24. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017;389:1218–1228.ArticlePubMed
  • 25. Vindigni SM, Zisman TL, Suskind DL, Damman CJ. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol 2016;9:606–625.ArticlePubMedPMC
  • 26. Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2016;14:1433–1438.ArticlePubMedPMC
  • 27. Newman KM, Rank KM, Vaughn BP, Khoruts A. Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gut Microbes 2017;8:303–309.ArticlePubMedPMC
  • 28. Khanna S, Shin A, Kelly CP. Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the clinical practice updates committee of the AGA institute. Clin Gastroenterol Hepatol 2017;15:166–174.ArticlePubMed
  • 29. Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018;3:17–24.ArticlePubMed
  • 30. Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep 2017;7:1529.ArticlePubMedPMCPDF
  • 31. Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 2017;66:1727–1738.ArticlePubMedPMC
  • 32. Jayasinghe TN, Chiavaroli V, Holland DJ, Cutfield WS, O’Sullivan JM. The new era of treatment for obesity and metabolic disorders: evidence and expectations for gut microbiome transplantation. Front Cell Infect Microbiol 2016;6:15.ArticlePubMedPMC
  • 33. Ruggiero M. Fecal microbiota transplantation and the brain microbiota in neurological diseases. Clin Endosc 2016;49:579.ArticlePubMedPMCPDF
  • 34. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014;109:1065–1071.ArticlePubMedPMCPDF
  • 35. Kelly BJ, Tebas P. Clinical practice and infrastructure review of fecal microbiota transplantation for Clostridium difficile infection. Chest 2018;153:266–277.ArticlePubMedPMC
  • 36. McCune VL, Struthers JK, Hawkey PM. Faecal transplantation for the treatment of Clostridium difficile infection: a review. Int J Antimicrob Agents 2014;43:201–206.ArticlePubMed
  • 37. Brandt LJ. American Journal of Gastroenterology lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 2013;108:177–185.ArticlePubMedPDF
  • 38. Allegretti JR, Kassam Z, Osman M, Budree S, Fischer M, Kelly CR. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest Endosc 2018;87:18–29.ArticlePubMed
  • 39. Kim KO, Schwartz M, Gluck M. Reducing cost and scheduling complexity of fecal microbiota transplantation by using universal donor over patients-directed donors in patients with recurrent Clostrodium difficile infections. Gastroenterology 2018;154(6 Suppl 1):S191.Article
  • 40. Edelstein C, Daw JR, Kassam Z. Seeking safe stool: Canada needs a universal donor model. CMAJ 2016;188:E431–E432.ArticlePubMedPMC
  • 41. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013;108:500–508.ArticlePubMedPDF
  • 42. OpenBiome. OpenBiome quality & safety program [Internet]. Cambridge (MA): OpenBiome; c2017 c2017 [updated 2017 May; cited 2018 Apr 26]. Available from: https://www.openbiome.org/safety
  • 43. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2016;315:142–149.ArticlePubMed
  • 44. Kazerouni A, Burgess J, Burns LJ, Wein LM. Optimal screening and donor management in a public stool bank. Microbiome 2015;3:75.ArticlePubMedPMC
  • 45. Smith M, Kassam Z, Edelstein C, Burgess J, Alm E. OpenBiome remains open to serve the medical community. Nat Biotechnol 2014;32:867.ArticlePubMedPDF
  • 46. Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin North Am 2015;29:37–50.ArticlePubMedPMC
  • 47. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53:994–1002.ArticlePubMedPDF
  • 48. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014;312:1772–1778.ArticlePubMed
  • 49. Fischer M, Kao D, Mehta SR, et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol 2016;111:1024–1031.ArticlePubMedPDF
  • 50. Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection 2012;40:643–648.ArticlePubMedPDF
  • 51. Sofi AA, Silverman AL, Khuder S, Garborg K, Westerink JM, Nawras A. Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection-pooled data analysis and a systematic review. Scand J Gastroenterol 2013;48:266–273.ArticlePubMed
  • 52. Obi O, Hampton D, Anderson T, et al. Fecal microbiota transplant for treatment of resistant C. difficile infection using a standardized protocol: a community hospital experience: 2172. Am J Gastroenterol 2014;109(Suppl 2):S629.ArticlePubMed
  • 53. Baxter M, Ahmad T, Colville A, Sheridan R. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis 2015;61:136–137.ArticlePubMedPDF
  • 54. Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012;55:1652–1658.ArticlePubMedPDF
  • 55. Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2017;318:1985–1993.ArticlePubMedPMC
  • 56. Allegretti JR, Fischer M, Papa E, et al. Fecal microbiota transplantation delivered via oral capsules achieves microbial engraftment similar to traditional delivery modalities: safety, efficacy and engraftment results from a multi-center cluster randomized dose-finding study. Gastroenterology 2016;150(4 Suppl 1):S540.Article
  • 57. Allegretti JR, Allegretti AS, Phelps E, Xu H, Fischer M, Kassam Z. Classifying fecal microbiota transplantation failure: an observational study examining timing and characteristics of fecal microbiota transplantation failures. Clin Gastroenterol Hepatol 2018;16:1832–1833.ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Gut Microbiota Modulation and Its Implications on Neuropathic Pain: A Comprehensive Literature Review
      Alberto Corriero, Mariateresa Giglio, Francesco Inchingolo, Antonio Moschetta, Giustino Varrassi, Filomena Puntillo
      Pain and Therapy.2024; 13(1): 33.     CrossRef
    • Role of gut microbiota in tumorigenesis and antitumoral therapies: an updated review
      Shivani Singhal, Renu Bhadana, Buddhi Prakash Jain, Akash Gautam, Shweta Pandey, Vibha Rani
      Biotechnology and Genetic Engineering Reviews.2024; 40(4): 3716.     CrossRef
    • Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives
      Katharine A. Seton, José A. Espejo-Oltra, Karen Giménez-Orenga, Rik Haagmans, Donia J. Ramadan, Jesper Mehlsen
      Journal of Clinical Medicine.2024; 13(2): 325.     CrossRef
    • From Gut to Brain: Unraveling the Intricate Link Between Microbiome and Stroke
      Neha Raghani, Humzah Postwala, Yesha Shah, Mehul Chorawala, Priyajeet Parekh
      Probiotics and Antimicrobial Proteins.2024; 16(6): 2039.     CrossRef
    • Nontraditional Treatment of Hepatic Encephalopathy
      Jasleen Singh, Brittney Ibrahim, Steven-Huy Han
      Clinics in Liver Disease.2024; 28(2): 297.     CrossRef
    • Pathophysiology of acute lung injury in patients with acute brain injury: the triple-hit hypothesis
      Mairi Ziaka, Aristomenis Exadaktylos
      Critical Care.2024;[Epub]     CrossRef
    • Short-Chain Fatty Acid (SCFA) as a Connecting Link between Microbiota and Gut-Lung Axis─A Potential Therapeutic Intervention to Improve Lung Health
      Anjali Verma, Tannu Bhagchandani, Ankita Rai, Nikita, Urvinder Kaur Sardarni, Neel Sarovar Bhavesh, Sameer Gulati, Rupali Malik, Ravi Tandon
      ACS Omega.2024; 9(13): 14648.     CrossRef
    • Staphylococcus aureus Infections and Human Intestinal Microbiota
      Aotong Liu, Shari Garrett, Wanqing Hong, Jilei Zhang
      Pathogens.2024; 13(4): 276.     CrossRef
    • Crosstalk between COVID-19 and the gut-brain axis: a gut feeling
      Nida Kalam, Vinod R M T Balasubramaniam
      Postgraduate Medical Journal.2024; 100(1186): 539.     CrossRef
    • Bacterial consortia-The latest arsenal to inflammatory bowel disease bacteriotherapy
      Mukta Gupta, Bhupinder Kapoor, Monica Gulati
      Medicine in Microecology.2024; 20: 100107.     CrossRef
    • The Importance of Microbiota and Fecal Microbiota Transplantation in Pancreatic Disorders
      Adrian Boicean, Cristian Ichim, Samuel Bogdan Todor, Paula Anderco, Mirela Livia Popa
      Diagnostics.2024; 14(9): 861.     CrossRef
    • Alternative treatment of recurrent Clostridioides difficile infection in adults by fecal transplantation: an overview of phase I–IV studies from Clinicaltrials.gov
      Najla A. Obaid
      Frontiers in Microbiology.2024;[Epub]     CrossRef
    • Oral microbiome dysbiosis and gastrointestinal diseases: a narrative review
      Maged Tharwat Elghannam, Moataz Hassan Hassanien, Yosry Abdelrahman Ameen, Emad Abdelwahab Turky, Gamal Mohammed ELattar, Ahmed Aly ELRay, Mohammed Darwish ELTalkawy
      Egyptian Liver Journal.2024;[Epub]     CrossRef
    • Effects of the gut microbiota and its metabolite short-chain fatty acids on endometriosis
      Menghe Liu, Ru Peng, Chunfang Tian, Jianping Shi, Jiannan Ma, Ruiwen Shi, Xiao Qi, Rongwei Zhao, Haibin Guan
      Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
    • Unraveling the Microbiome–Human Body Axis: A Comprehensive Examination of Therapeutic Strategies, Interactions and Implications
      Gabriel Olteanu, Maria-Alexandra Ciucă-Pană, Ștefan Sebastian Busnatu, Dumitru Lupuliasa, Sorinel Marius Neacșu, Magdalena Mititelu, Adina Magdalena Musuc, Corina-Bianca Ioniță-Mîndrican, Steluța Constanța Boroghină
      International Journal of Molecular Sciences.2024; 25(10): 5561.     CrossRef
    • Exploring the lung-gut direction of the gut-lung axis in patients with ARDS
      Mairi Ziaka, Aristomenis Exadaktylos
      Critical Care.2024;[Epub]     CrossRef
    • Unraveling the gut microbiome’s contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives
      Eileen Tabrizi, Fatemeh Pourteymour Fard Tabrizi, Gehad Mahmoud Khaled, Michael P. Sestito, Saeid Jamie, Brian A. Boone
      Frontiers in Immunology.2024;[Epub]     CrossRef
    • Exploring Fecal Microbiota Transplantation for Modulating Inflammation in Parkinson’s Disease: A Review of Inflammatory Markers and Potential Effects
      Karol Sadowski, Weronika Zając, Łukasz Milanowski, Dariusz Koziorowski, Monika Figura
      International Journal of Molecular Sciences.2024; 25(14): 7741.     CrossRef
    • Strengthening the Korean Network of Microbial Culture Collections in the Microbiome Era
      Yiseul Kim, Hyang Min Cheong, Grace Choi, Kyung-Min Choi, Eu Jin Chung, Ahran Kim, Song-Gun Kim, Soonok Kim, Jung-Sook Lee, Dong-Kun Yang, Seung-Beom Hong
      Mycobiology.2024; 52(4): 207.     CrossRef
    • The role of the gut microbiome in neuroinflammation and chemotherapy-induced peripheral neuropathy
      Svetlana Shatunova, Rubina Aktar, Madusha Peiris, Jia Yu Peppermint Lee, Irina Vetter, Hana Starobova
      European Journal of Pharmacology.2024; 979: 176818.     CrossRef
    • The Brain–Gut–Bone Axis in Neurodegenerative Diseases: Insights, Challenges, and Future Prospects
      Rong Li, Zong Miao, Yu'e Liu, Xiao Chen, Hongxiang Wang, Jiacan Su, Juxiang Chen
      Advanced Science.2024;[Epub]     CrossRef
    • Fecal microbiota transplantation accelerates restoration of florfenicol-disturbed intestinal microbiota in a fish model
      Zhuoran Han, Jingfeng Sun, Boyun Jiang, Kun Chen, Lunhua Ge, Zhongshi Sun, Anli Wang
      Communications Biology.2024;[Epub]     CrossRef
    • The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials
      Ridhima Kaul, Pradipta Paul, Manale Harfouche, Muhammad Ayyan, Sa'ad Laws, Ali Chaari
      Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(8): 103118.     CrossRef
    • Clinical efficacy and safety of faecal microbiota transplantation in the treatment of irritable bowel syndrome: a systematic review, meta-analysis and trial sequential analysis
      Shao-Wei Lo, Tsung-Hsuan Hung, Yen-Tsen Lin, Chun-Shen Lee, Chiung-Yu Chen, Ching-Ju Fang, Pei-Chun Lai
      European Journal of Medical Research.2024;[Epub]     CrossRef
    • ‘Does this fecal microbiota transplant work?’ Quality assurance of capsule based fecal microbiota transplant production
      Emil Ainsworth Jochumsen, Maja Skov Kragsnaes, Anna Christine Nilsson, Kristina Fruerlund Rasmussen, Torkell Ellingsen, Mie Agerbaek Juul, Jens Kjeldsen, Dorte Kinggaard Holm
      Scandinavian Journal of Gastroenterology.2024; 59(11): 1234.     CrossRef
    • Beyond the organ: lung microbiome shapes transplant indications and outcomes
      Florian Ponholzer, Christina Bogensperger, Felix Julius Krendl, Christoph Krapf, Julia Dumfarth, Stefan Schneeberger, Florian Augustin
      European Journal of Cardio-Thoracic Surgery.2024;[Epub]     CrossRef
    • The role of gut microbiota, immune system, and autophagy in the pathogenesis of inflammatory bowel disease: Molecular mechanisms and therapeutic approaches
      Beatrice Garavaglia, Letizia Vallino, Angela Amoruso, Marco Pane, Alessandra Ferraresi, Ciro Isidoro
      Aspects of Molecular Medicine.2024; 4: 100056.     CrossRef
    • Combating antimicrobial resistance in osteoarticular infections: Current strategies and future directions
      Madhan Jeyaraman, Tarun Jayakumar, Naveen Jeyaraman, Arulkumar Nallakumarasamy, Swaminathan Ramasubramanian, Sathish Muthu, Vijay Kumar Jain
      Journal of Clinical Orthopaedics and Trauma.2024; 58: 102791.     CrossRef
    • New insights into methods to measure biological age: a literature review
      Aanchal Mathur, Sebastien Taurin, Sfoug Alshammary
      Frontiers in Aging.2024;[Epub]     CrossRef
    • Modulation of efferocytosis and inflammation resolution by live and non-live probiotics through gut microbiota interactions in preclinical and clinical studies
      Mona Arianejad, Farnaz Tajeddini, Mina Zareardalan, Fatemeh Hosseinpour-Soleimani, Mohsen Sisakht, Amir Tajbakhsh, Mohammad-Taha Pirsalehi, Manica Negahdaripour
      Food Bioscience.2024; 62: 105498.     CrossRef
    • A reappraisal on amyloid cascade hypothesis: the role of chronic infection in Alzheimer’s disease
      Zhi Xin Phuna, Priya Madhavan
      International Journal of Neuroscience.2023; 133(10): 1071.     CrossRef
    • Recognition and attitudes of Korean physicians toward fecal microbiota transplantation: a survey study
      Tae-Geun Gweon, Yoo Jin Lee, Sung Kyun Yim, Seung Yong Kim, Chang Hwan Choi, Young-Seok Cho
      The Korean Journal of Internal Medicine.2023; 38(1): 48.     CrossRef
    • Gut-oriented disease modifying therapy for Parkinson's disease
      Chin-Hsien Lin, Hsin-Chih Lai, Ming-Shiang Wu
      Journal of the Formosan Medical Association.2023; 122(1): 9.     CrossRef
    • Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options
      Concetta Panebianco, Annacandida Villani, Adele Potenza, Enrica Favaro, Concetta Finocchiaro, Francesco Perri, Valerio Pazienza
      International Journal of Molecular Sciences.2023; 24(3): 1849.     CrossRef
    • Beneficial insights into postbiotics against colorectal cancer
      Dingka Song, Xiuli Wang, Yongjing Ma, Ning-Ning Liu, Hui Wang
      Frontiers in Nutrition.2023;[Epub]     CrossRef
    • Metabolic-Associated Fatty Liver Disease and the Gut Microbiota
      Thomas M. Barber, Petra Hanson, Martin O. Weickert
      Endocrinology and Metabolism Clinics of North America.2023; 52(3): 485.     CrossRef
    • Beyond faecal microbiota transplantation, the non-negligible role of faecal virome or bacteriophage transplantation
      Dengyu Wu, Chenguang Zhang, Yanli Liu, Junhu Yao, Xiaojun Yang, Shengru Wu, Juan Du, Xin Yang
      Journal of Microbiology, Immunology and Infection.2023; 56(5): 893.     CrossRef
    • Polymerization in living organisms
      Dan Wu, Jiaqi Lei, Zhankui Zhang, Feihe Huang, Marija Buljan, Guocan Yu
      Chemical Society Reviews.2023; 52(9): 2911.     CrossRef
    • Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors
      Noelia Silva-Pilipich, Ángela Covo-Vergara, Cristian Smerdou
      Cancers.2023; 15(8): 2352.     CrossRef
    • The role of microbiota and its modulation in colonic diverticular disease
      Giovanni Marasco, Francesco Buttitta, Cesare Cremon, Maria Raffaella Barbaro, Vincenzo Stanghellini, Giovanni Barbara
      Neurogastroenterology & Motility.2023;[Epub]     CrossRef
    • The gastrointestinal-brain-microbiota axis: a promising therapeutic target for ischemic stroke
      Yan-hao Wei, Ren-tang Bi, Yan-mei Qiu, Chun-lin Zhang, Jian-zhuang Li, Ya-nan Li, Bo Hu
      Frontiers in Immunology.2023;[Epub]     CrossRef
    • Mikrobiyotanın Enfeksiyon Hastalıklarındaki Rolü
      Hamide KAYA, Eyyüp KAYA
      Black Sea Journal of Health Science.2023; 6(3): 516.     CrossRef
    • Intestinal stem cells and gut microbiota therapeutics: hype or hope?
      Ahmad Naqiuddin Ahmad Sophien, Amirah Syamimi Jusop, Gee Jun Tye, Yuen-Fen Tan, Wan Safwani Wan Kamarul Zaman, Fazlina Nordin
      Frontiers in Medicine.2023;[Epub]     CrossRef
    • Microbiome-Based Therapies in Parkinson’s Disease: Can Tuning the Microbiota Become a Viable Therapeutic Strategy?
      Adejoke Y. Onaolapo, Folusho O. Ojo, Anthony T. Olofinnade, Joshua Falade, Ismail A. Lawal, Olakunle J. Onaolapo
      CNS & Neurological Disorders - Drug Targets.2023; 22(9): 1355.     CrossRef
    • Drug and gut microbe relationships: Moving beyond antibiotics
      Shreyas V. Kumbhare, Inti Pedroso, Juan A. Ugalde, Valeria Márquez-Miranda, Ranjan Sinha, Daniel E. Almonacid
      Drug Discovery Today.2023; 28(11): 103797.     CrossRef
    • Factors Associated With Fecal Microbiota Transplant Failure in the Treatment of Recurrent Clostridioides difficile Infection: A Single-Center Retrospective Study
      Fatima Warraich, Syed H Sohail, Alexander Knee, Jacob Smith, Hans Schlecht, Daniel Skiest
      Cureus.2023;[Epub]     CrossRef
    • Flavonoids: Their putative neurologic roles, epigenetic changes, and gut microbiota alterations in Parkinson’s disease
      Yasemin Açar, Duygu Ağagündüz, Paola De Cicco, Raffaele Capasso
      Biomedicine & Pharmacotherapy.2023; 168: 115788.     CrossRef
    • Fecal microbiota transplantation: History, procedure and regulatory considerations
      Thanush D, M.P. Venkatesh
      La Presse Médicale.2023; 52(4): 104204.     CrossRef
    • Gut microbiota of Suncus murinus, a naturally obesity-resistant animal, improves the ecological diversity of the gut microbiota in high-fat-diet-induced obese mice
      Mingshou Zhang, Ting Yang, Rujia Li, Ke Ren, Jun Li, Maozhang He, Juefei Chen, Shuang-Qin Yi, Farah Al-Marzooq
      PLOS ONE.2023; 18(11): e0293213.     CrossRef
    • Role of Fecal Microbiota Transplantation in Managing Clostridium Difficile Infection and Inflammatory Bowel Disease: A Narrative Review
      Haider Ghazanfar, Sameer Kandhi, Trishna Acherjee, Zaheer A Qureshi, Mohammed Shaban, Diaz Saez Yordanka, Dessiree Cordero, Siddarth Chinta, Abhilasha Jyala, Harish Patel
      Cureus.2023;[Epub]     CrossRef
    • Escherichia coli O157: H7 sepsis following fecal microbiota transplant in an IgA-deficient inflammatory bowel disease patient
      Landen S Burstiner, Jared Silver, Logan J Burstiner, Arian Teymoorian, Kumar Pallav, Demarre Jones, Anna Owings, Sarah Glover
      Gastroenterology Report.2022;[Epub]     CrossRef
    • Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients
      Nirja Mehta, Tiffany Wang, Rachel J. Friedman-Moraco, Cynthia Carpentieri, Aneesh K. Mehta, Nadine Rouphael, Tanvi Dhere, Christian P. Larsen, Colleen S. Kraft, Michael H. Woodworth, Romney M. Humphries
      Journal of Clinical Microbiology.2022;[Epub]     CrossRef
    • Towards Engineering an Ecosystem: A Review of Computational Approaches to Explore and Exploit the Human Microbiome for Healthcare
      Anirban Dutta, Sharmila S. Mande
      Transactions of the Indian National Academy of Engineering.2022; 7(1): 29.     CrossRef
    • Storage of soil microbiome for application in sustainable agriculture: prospects and challenges
      Annapurna Bhattacharjee, Shubham Dubey, Shilpi Sharma
      Environmental Science and Pollution Research.2022; 29(3): 3171.     CrossRef
    • Microbiota and body weight control: Weight watchers within?
      Serena Boscaini, Sarah-Jane Leigh, Aonghus Lavelle, Rubén García-Cabrerizo, Timothy Lipuma, Gerard Clarke, Harriët Schellekens, John F. Cryan
      Molecular Metabolism.2022; 57: 101427.     CrossRef
    • The gut microbiota can be a potential regulator and treatment target of bone metastasis
      Kelly F. Contino, Hariom Yadav, Yusuke Shiozawa
      Biochemical Pharmacology.2022; 197: 114916.     CrossRef
    • Stochastic microbiome assembly depends on context
      Eric W. Jones, Jean M. Carlson, David A. Sivak, William B. Ludington
      Proceedings of the National Academy of Sciences.2022;[Epub]     CrossRef
    • Coronavirus: An emerging and future challenge for dental clinicians
      Rohit Singh, Aashana Goel, Pooja Pani, BhupenderSingh Negi, JagadishPrasad Rajguru, NagaveniS Somayaji
      National Journal of Maxillofacial Surgery.2022; 13(1): 20.     CrossRef
    • Novel Role of Ghrelin Receptor in Gut Dysbiosis and Experimental Colitis in Aging
      Ji Yeon Noh, Chia-Shan Wu, Jennifer A. A. DeLuca, Sridevi Devaraj, Arul Jayaraman, Robert C. Alaniz, Xiao-Di Tan, Clinton D. Allred, Yuxiang Sun
      International Journal of Molecular Sciences.2022; 23(4): 2219.     CrossRef
    • The effect of fecal microbial transplant on intestinal microbial composition in short‐bowel neonatal piglets
      Tierah Hinchliffe, Mirielle L. Pauline, Pamela R. Wizzard, Juan Jovel, Patrick N. Nation, Paul W. Wales, Karen L. Madsen, Justine M. Turner
      Journal of Parenteral and Enteral Nutrition.2022; 46(6): 1393.     CrossRef
    • Microbiota medicine: towards clinical revolution
      Prisca Gebrayel, Carole Nicco, Souhaila Al Khodor, Jaroslaw Bilinski, Elisabetta Caselli, Elena M. Comelli, Markus Egert, Cristina Giaroni, Tomasz M. Karpinski, Igor Loniewski, Agata Mulak, Julie Reygner, Paulina Samczuk, Matteo Serino, Mariusz Sikora, An
      Journal of Translational Medicine.2022;[Epub]     CrossRef
    • Gut dysbiosis and age-related neurological diseases in females
      Janelle M. Korf, Bhanu P. Ganesh, Louise D. McCullough
      Neurobiology of Disease.2022; 168: 105695.     CrossRef
    • The Influence of Gut Dysbiosis in the Pathogenesis and Management of Ischemic Stroke
      Saravana Babu Chidambaram, Annan Gopinath Rathipriya, Arehally M. Mahalakshmi, Sonali Sharma, Tousif Ahmed Hediyal, Bipul Ray, Tuladhar Sunanda, Wiramon Rungratanawanich, Rajpal Singh Kashyap, M. Walid Qoronfleh, Musthafa Mohamed Essa, Byoung-Joon Song, T
      Cells.2022; 11(7): 1239.     CrossRef
    • Fecal microbiota transplantation for Carbapenem-Resistant Enterobacteriaceae: A systematic review
      Jordán Macareño-Castro, Adán Solano-Salazar, Le Thanh Dong, Md Mohiuddin, J. Luis Espinoza
      Journal of Infection.2022; 84(6): 749.     CrossRef
    • Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer
      Raghad Khalid AL-Ishaq, Lenka Koklesova, Peter Kubatka, Dietrich Büsselberg
      Cancers.2022; 14(9): 2140.     CrossRef
    • The right bug in the right place: opportunities for bacterial vaginosis treatment
      Shengru Wu, Luisa Warchavchik Hugerth, Ina Schuppe-Koistinen, Juan Du
      npj Biofilms and Microbiomes.2022;[Epub]     CrossRef
    • Any Future for Faecal Microbiota Transplantation as a Novel Strategy for Gut Microbiota Modulation in Human and Veterinary Medicine?
      Martina Takáčová, Alojz Bomba, Csilla Tóthová, Alena Micháľová, Hana Turňa
      Life.2022; 12(5): 723.     CrossRef
    • Adverse events of intestinal microbiota transplantation in randomized controlled trials: a systematic review and meta-analysis
      Chong Chen, Liyu Chen, Dayong Sun, Cailan Li, Shiheng Xi, Shihua Ding, Rongrong Luo, Yan Geng, Yang Bai
      Gut Pathogens.2022;[Epub]     CrossRef
    • Clinical Translation of Microbiome Research in Alopecia Areata: A New Perspective?
      Fabio Rinaldi, Anna Trink, Angela Papale, Giammaria Giuliani, Daniela Pinto
      Cosmetics.2022; 9(3): 55.     CrossRef
    • Metagenomic profiles of the early life microbiome of Indonesian inpatient neonates and their influence on clinical characteristics
      Radhian Amandito, Amarila Malik, Rinawati Rohsiswatmo
      Scientific Reports.2022;[Epub]     CrossRef
    • Gut Microbiota Composition Associated with Clostridioides difficile Colonization and Infection
      Elisa Martinez, Bernard Taminiau, Cristina Rodriguez, Georges Daube
      Pathogens.2022; 11(7): 781.     CrossRef
    • Successful Fecal Microbiota Transplant Delivered by Foley Catheter Through a Loop Ileostomy in a Patient With Severe Complicated Clostridioides difficile Infection
      Shawn Philip, Omar Tageldin, Muhammed Sohail Mansoor, Seth Richter
      ACG Case Reports Journal.2022; 9(7): e00801.     CrossRef
    • Gut–Brain Axis, Neurodegeneration and Mental Health: A Personalized Medicine Perspective
      Alisha Chunduri, S. Deepak Mohan Reddy, M. Jahanavi, C. Nagendranatha Reddy
      Indian Journal of Microbiology.2022; 62(4): 505.     CrossRef
    • Design and manufacture of a lyophilised faecal microbiota capsule formulation to GMP standards
      Nur Masirah M. Zain, Daniëlle ter Linden, Andrew K. Lilley, Paul G. Royall, Sophia Tsoka, Kenneth D. Bruce, A. James Mason, Grace B. Hatton, Elizabeth Allen, Simon D. Goldenberg, Ben Forbes
      Journal of Controlled Release.2022; 350: 324.     CrossRef
    • The gut microbiota and endometriosis: From pathogenesis to diagnosis and treatment
      Rui Qin, Gengren Tian, Junbao Liu, Lu Cao
      Frontiers in Cellular and Infection Microbiology.2022;[Epub]     CrossRef
    • Atipical course of clostridial colitis in child with Hodgkin’s lymphoma
      A. V. Lyanguzov, S. V. Ignatyev, S. L. Kalinina, O. M. Tselousova, I. P. Tataurova, D. A. Dyakonov
      Russian Journal of Pediatric Hematology and Oncology.2022; 9(3): 107.     CrossRef
    • Gut microbiome sheds light on the development and treatment of abdominal aortic aneurysm
      Xuebin Ling, Wei Jie, Xue Qin, Shuya Zhang, Kaijia Shi, Tianfa Li, Junli Guo
      Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
    • Fecal microbiota transplantation in irritable bowel syndrome: A meta-analysis of randomized controlled trials
      Chatpol Samuthpongtorn, Piyawat Kantagowit, Rapat Pittayanon, Tanisa Patcharatrakul, Sutep Gonlachanvit
      Frontiers in Medicine.2022;[Epub]     CrossRef
    • Mechanisms Leading to Gut Dysbiosis in COVID-19: Current Evidence and Uncertainties Based on Adverse Outcome Pathways
      Laure-Alix Clerbaux, Julija Filipovska, Amalia Muñoz, Mauro Petrillo, Sandra Coecke, Maria-Joao Amorim, Lucia Grenga
      Journal of Clinical Medicine.2022; 11(18): 5400.     CrossRef
    • Orchestration of Obesolytic Activity of Microbiome: Metabiotics at Centre Stage
      Bhupinder Kapoor, Apoorva Singh, Monica Gulati, Sachin Kumar Singh, Pooja Rani, Qushmua Alzahrani, Kamal Dua, Harish Dureja, Leander Corrie
      Current Drug Metabolism.2022; 23(2): 90.     CrossRef
    • Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention
      Lucrezia Irene Maria Campagnoli, Nicoletta Marchesi, Mariapia Vairetti, Alessia Pascale, Andrea Ferrigno, Annalisa Barbieri
      Cells.2022; 11(18): 2827.     CrossRef
    • Effects of a farm-specific fecal microbial transplant (FMT) product on clinical outcomes and fecal microbiome composition in preweaned dairy calves
      Giovana S. Slanzon, Benjamin J. Ridenhour, Lindsay M. Parrish, Sophie C. Trombetta, Dale A. Moore, William M. Sischo, Craig S. McConnel, Juan J. Loor
      PLOS ONE.2022; 17(10): e0276638.     CrossRef
    • Fecal Microbiota Transplant in Immunotherapy-Resistant Melanoma: What Can We Expect in the Near Future?
      André Ferreira, Maria Teresa Neves, Ana Baleiras, Mariana Malheiro, Ana Martins
      Cureus.2022;[Epub]     CrossRef
    • Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials
      Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho, Nguan Soon Tan
      International Journal of Molecular Sciences.2022; 24(1): 158.     CrossRef
    • Role of alternatives to antibiotics in mitigating the antimicrobial resistance crisis
      Renu Gupta, Sangeeta Sharma
      Indian Journal of Medical Research.2022; 156(3): 464.     CrossRef
    • Fecal microbiota transplant and dermatologic disorders: A retrospective cohort study assessing the gut microbiome’s role in skin disease
      Ashley M Snyder, James Abbott, M Kyle Jensen, Aaron M Secrest
      World Journal of Dermatology.2021; 9(1): 1.     CrossRef
    • Do an Altered Gut Microbiota and an Associated Leaky Gut Affect COVID-19 Severity?
      Heenam Stanley Kim, Maria Gloria Dominguez Bello
      mBio.2021;[Epub]     CrossRef
    • Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment
      Magdalena Koszewicz, Joanna Jaroch, Anna Brzecka, Maria Ejma, Slawomir Budrewicz, Liudmila M. Mikhaleva, Cristian Muresanu, Pamela Schield, Siva G. Somasundaram, Cecil E. Kirkland, Marco Avila-Rodriguez, Gjumrakch Aliev
      Pharmacological Research.2021; 164: 105277.     CrossRef
    • Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders
      Michal Caspi, Amnon Wittenstein, Michal Kazelnik, Yarden Shor-Nareznoy, Rina Rosin-Arbesfeld
      Advanced Drug Delivery Reviews.2021; 169: 118.     CrossRef
    • A systematic review on the role of microbiota in the pathogenesis and treatment of eating disorders
      Elvira Anna Carbone, Pasquale D'Amato, Giuseppe Vicchio, Pasquale De Fazio, Cristina Segura-Garcia
      European Psychiatry.2021;[Epub]     CrossRef
    • An Oral FMT Capsule as Efficient as an Enema for Microbiota Reconstruction Following Disruption by Antibiotics, as Assessed in an In Vitro Human Gut Model
      Cécile Verdier, Sylvain Denis, Cyrielle Gasc, Lilia Boucinha, Ophélie Uriot, Dominique Delmas, Joël Dore, Corentin Le Camus, Carole Schwintner, Stéphanie Blanquet-Diot
      Microorganisms.2021; 9(2): 358.     CrossRef
    • Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes
      Yasaman Ghorbani, Katherine J. P. Schwenger, Johane P. Allard
      European Journal of Nutrition.2021; 60(5): 2361.     CrossRef
    • Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis
      Valentin Mocanu, Sabitha Rajaruban, Jerry Dang, Janice Y. Kung, Edward C. Deehan, Karen L. Madsen
      Journal of Clinical Medicine.2021; 10(5): 959.     CrossRef
    • Polymerization‐Mediated Multifunctionalization of Living Cells for Enhanced Cell‐Based Therapy
      Chao Pan, Juanjuan Li, Weiliang Hou, Sisi Lin, Lu Wang, Yan Pang, Yufeng Wang, Jinyao Liu
      Advanced Materials.2021;[Epub]     CrossRef
    • Association of Parkinson’s Disease With Microbes and Microbiological Therapy
      Zhao-Ji Chen, Cheng-Yu Liang, Li-Qing Yang, Si-Min Ren, Yan-Min Xia, Lei Cui, Xiao-Fang Li, Bu-Lang Gao
      Frontiers in Cellular and Infection Microbiology.2021;[Epub]     CrossRef
    • New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota
      Marina Lorente-Picón, Ariadna Laguna
      Biomolecules.2021; 11(3): 433.     CrossRef
    • Dietary Influences on the Microbiota–Gut–Brain Axis
      Thomas M. Barber, Georgios Valsamakis, George Mastorakos, Petra Hanson, Ioannis Kyrou, Harpal S. Randeva, Martin O. Weickert
      International Journal of Molecular Sciences.2021; 22(7): 3502.     CrossRef
    • Next Generation Fecal Microbiota Transplantation
      Tae-Geun Gweon, Soo-Young Na
      Clinical Endoscopy.2021; 54(2): 152.     CrossRef
    • Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank
      Justin Chen, Amanda Zaman, Bharat Ramakrishna, Scott W. Olesen
      Frontiers in Cellular and Infection Microbiology.2021;[Epub]     CrossRef
    • Alternatives to Antibiotics: A Symposium on the Challenges and Solutions for Animal Health and Production
      Todd R. Callaway, Hyun Lillehoj, Rungtip Chuanchuen, Cyril G. Gay
      Antibiotics.2021; 10(5): 471.     CrossRef
    • Recipient factors in faecal microbiota transplantation: one stool does not fit all
      Camille Danne, Nathalie Rolhion, Harry Sokol
      Nature Reviews Gastroenterology & Hepatology.2021; 18(7): 503.     CrossRef
    • Restoration of dysbiotic human gut microbiome for homeostasis
      Kunal Dixit, Diptaraj Chaudhari, Dhiraj Dhotre, Yogesh Shouche, Sunil Saroj
      Life Sciences.2021; 278: 119622.     CrossRef
    • Co-Encapsulated Synbiotics and Immobilized Probiotics in Human Health and Gut Microbiota Modulation
      Monika Kvakova, Izabela Bertkova, Jana Stofilova, Tor C. Savidge
      Foods.2021; 10(6): 1297.     CrossRef
    • How to Apply FMT More Effectively, Conveniently and Flexible – A Comparison of FMT Methods
      Adorján Varga, Béla Kocsis, Dávid Sipos, Péter Kása, Szabolcs Vigvári, Szilárd Pál, Fanni Dembrovszky, Kornélia Farkas, Zoltán Péterfi
      Frontiers in Cellular and Infection Microbiology.2021;[Epub]     CrossRef
    • Towards Understanding COVID-19: Molecular Insights, Co-infections, Associated Disorders, and Aging
      Elena L. Paley
      Journal of Alzheimer's Disease Reports.2021; 5(1): 571.     CrossRef
    • Is there a role of faecal microbiota transplantation in reducing antibiotic resistance burden in gut? A systematic review and Meta-analysis
      Priyanga Dharmaratne, Nannur Rahman, Anthony Leung, Margaret Ip
      Annals of Medicine.2021; 53(1): 662.     CrossRef
    • Review: The Nose as a Route for Therapy. Part 2 Immunotherapy
      Yorissa Padayachee, Sabine Flicker, Sophia Linton, John Cafferkey, Onn Min Kon, Sebastian L. Johnston, Anne K. Ellis, Martin Desrosiers, Paul Turner, Rudolf Valenta, Glenis Kathleen Scadding
      Frontiers in Allergy.2021;[Epub]     CrossRef
    • Opportunities for Nanomedicine in Clostridioides difficile Infection
      Pei-Wen Wang, Wei-Ting Lee, Ya-Na Wu, Dar-Bin Shieh
      Antibiotics.2021; 10(8): 948.     CrossRef
    • Editors' Choice of Noteworthy Clinical Endoscopy Publications in the First Decade
      Gwang Ha Kim, Kwang An Kwon, Do Hyun Park, Jimin Han
      Clinical Endoscopy.2021; 54(5): 633.     CrossRef
    • Fecal microbiota transplantation as a mean of overcoming immunotherapy-resistant cancers – hype or hope?
      Erez N. Baruch, Tanmay Gaglani, Jennifer A. Wargo
      Therapeutic Advances in Medical Oncology.2021;[Epub]     CrossRef
    • In-Vitro Characterization of Growth Inhibition against the Gut Pathogen of Potentially Probiotic Lactic Acid Bacteria Strains Isolated from Fermented Products
      Ji Young Jung, Sang-Soo Han, Z-Hun Kim, Myung Hoo Kim, Hye Kyeong Kang, Hyun Mi Jin, Mi Hwa Lee
      Microorganisms.2021; 9(10): 2141.     CrossRef
    • The role of gut and genital microbiota and the estrobolome in endometriosis, infertility and chronic pelvic pain
      Mary E Salliss, Leslie V Farland, Nichole D Mahnert, Melissa M Herbst-Kralovetz
      Human Reproduction Update.2021; 28(1): 92.     CrossRef
    • Frontiers in antibiotic alternatives for Clostridioides difficile infection
      Matthew Phanchana, Phurt Harnvoravongchai, Supapit Wongkuna, Tanaporn Phetruen, Wichuda Phothichaisri, Supakan Panturat, Methinee Pipatthana, Sitthivut Charoensutthivarakul, Surang Chankhamhaengdecha, Tavan Janvilisri
      World Journal of Gastroenterology.2021; 27(42): 7210.     CrossRef
    • Antibiotics at the crossroads – Do we have any therapeutic alternatives to control the emergence and spread of antimicrobial resistance?
      Mohan Bilikallahalli Sannathimmappa, Vinod Nambiar, Rajeev Aravindakshan
      Journal of Education and Health Promotion.2021; 10(1): 438.     CrossRef
    • Expert opinion on fecal microbiota transplantation for the treatment of Clostridioides difficile infection and beyond
      Vinod Kumar, Monika Fischer
      Expert Opinion on Biological Therapy.2020; 20(1): 73.     CrossRef
    • Food ingredients in human health: Ecological and metabolic perspectives implicating gut microbiota function
      Qinglong Wu, Tingtao Chen, Hani El-Nezami, Tor C. Savidge
      Trends in Food Science & Technology.2020; 100: 103.     CrossRef
    • Delivery routes for faecal microbiota transplants: Available, anticipated and aspired
      Monica Gulati, Sachin Kumar Singh, Leander Corrie, Indu Pal Kaur, Lipika Chandwani
      Pharmacological Research.2020; 159: 104954.     CrossRef
    • Evaluation of metabolites levels in feces of patients with inflammatory bowel diseases
      E.S. Zhgun, Y.V. Kislun, T.N. Kalachniuk, V.A. Veselovsky, A.S. Urban, P.O. Tikhonova, A.V. Pavlenko, G.N. Ilchenko, E.N. Ilina
      Biomeditsinskaya Khimiya.2020; 66(3): 233.     CrossRef
    • Gut Microbiota in Acute Ischemic Stroke: From Pathophysiology to Therapeutic Implications
      Denise Battaglini, Pedro Moreno Pimentel-Coelho, Chiara Robba, Claudia C. dos Santos, Fernanda Ferreira Cruz, Paolo Pelosi, Patricia Rieken Macedo Rocco
      Frontiers in Neurology.2020;[Epub]     CrossRef
    • Intestinal Microbiota and Cardiovascular Diseases
      Protásio L. da Luz, Elisa Alberton Haas, Desiderio Favarato
      International Journal of Cardiovascular Sciences.2020;[Epub]     CrossRef
    • The Other Obesity Epidemic—Of Drugs and Bugs
      Adonis Sfera, Carolina Osorio, Eddie Lee Diaz, Gerald Maguire, Michael Cummings
      Frontiers in Endocrinology.2020;[Epub]     CrossRef
    • Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non‐small cell lung cancer (AB‐CLICaP)
      Alejandro Ruiz‐Patiño, Feliciano Barrón, Andrés F. Cardona, Luis Corrales, Luis Mas, Claudio Martín, Zyanya L. Zatarain‐Barrón, Gonzalo Recondo, Luisa Ricaurte, Leonardo Rojas, Pilar Archila, July Rodríguez, Carolina Sotelo, Lucia Viola, Carlos Vargas, He
      Thoracic Cancer.2020; 11(9): 2552.     CrossRef
    • The Effectiveness of Multi-Session FMT Treatment in Active Ulcerative Colitis Patients: A Pilot Study
      Dorota Mańkowska-Wierzbicka, Marta Stelmach-Mardas, Marcin Gabryel, Hanna Tomczak, Marzena Skrzypczak-Zielińska, Oliwia Zakerska-Banaszak, Anna Sowińska, Dagmara Mahadea, Alina Baturo, Łukasz Wolko, Ryszard Słomski, Agnieszka Dobrowolska
      Biomedicines.2020; 8(8): 268.     CrossRef
    • Evolving Technologies in Gastrointestinal Microbiome Era and Their Potential Clinical Applications
      Abraham Ajayi, Tolulope Jolaiya, Stella Smith
      Journal of Clinical Medicine.2020; 9(8): 2565.     CrossRef
    • Modification of fecal microbiota as a mediator of effective weight loss and metabolic benefits following bariatric surgery
      Dominic Oduro-Donkor, Mark C. Turner, Sebastien Farnaud, Derek Renshaw, Ioannis Kyrou, Petra Hanson, John Hattersley, Martin O. Weickert, Vinod Menon, Harpal S Randeva, Thomas M. Barber
      Expert Review of Endocrinology & Metabolism.2020; 15(5): 363.     CrossRef
    • Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis
      Luciane de Fátima Caldeira, Helena H. Borba, Fernanda S. Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo, Udai P. Singh
      PLOS ONE.2020; 15(9): e0238910.     CrossRef
    • Gut Microbiota and Epilepsy: A Systematic Review on Their Relationship and Possible Therapeutics
      Alina Arulsamy, Qian Ying Tan, Vinod Balasubramaniam, Terence J. O’Brien, Mohd. Farooq Shaikh
      ACS Chemical Neuroscience.2020; 11(21): 3488.     CrossRef
    • Evaluation of the Levels of Metabolites in Feces of Patients with Inflammatory Bowel Diseases
      E. S. Zhgun, Y. V. Kislun, T. N. Kalachniuk, V. A. Veselovsky, A. S. Urban, P. O. Tikhonova, A. V. Pavlenko, G. N. Ilchenko, E. N. Ilina
      Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry.2020; 14(4): 312.     CrossRef
    • Clinical characteristics influence cultivable-bacteria composition in the meconium of Indonesian neonates
      Kristien Juni Thandwi Jonathan, Grasella Ong, Firsty Amanah Prasetyaningsih, Radhian Amandito, Rinawati Rohsiswatmo, Amarila Malik
      Heliyon.2020; 6(12): e05576.     CrossRef
    • Synthetic Biology Approaches in the Development of Engineered Therapeutic Microbes
      Minjeong Kang, Donghui Choe, Kangsan Kim, Byung-Kwan Cho, Suhyung Cho
      International Journal of Molecular Sciences.2020; 21(22): 8744.     CrossRef
    • Electroactive Smart Materials: Novel Tools for Tailoring Bacteria Behavior and Fight Antimicrobial Resistance
      Margarida M. Fernandes, Estela O. Carvalho, Senentxu Lanceros-Mendez
      Frontiers in Bioengineering and Biotechnology.2019;[Epub]     CrossRef
    • Investiture of next generation probiotics on amelioration of diseases – Strains do matter
      Tzu-Lung Lin, Ching-Chung Shu, Wei-Fan Lai, Chi-Meng Tzeng, Hsin-Chih Lai, Chia-Chen Lu
      Medicine in Microecology.2019; 1-2: 100002.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Fecal Microbiota Transplantation: An Update on Clinical Practice
      Clin Endosc. 2019;52(2):137-143.   Published online March 26, 2019
      DOI: https://doi.org/10.5946/ce.2019.009
      Close
    • XML DownloadXML Download
    Fecal Microbiota Transplantation: An Update on Clinical Practice
    Fecal Microbiota Transplantation: An Update on Clinical Practice
    Exclusion criteriaa)
    Age <18 yr or >65 yr
    BMI >30 kg/m2
    Metabolic syndrome
    Moderate to severe undernutrition
    History of antibiotics use in the last 6 mo
    Diarrhea within the last 3–6 mo
    History of Clostridium difficile colitis
    Immune disorder or use of immunosuppressive medications
    History of drug use or other recent risk factor for HIV or viral hepatitis
    History of travel to a tropical region in last 3 mo
    Any gastrointestinal illness (IBD, IBS, gastrointestinal malignancy, or major surgery) or complaints
    History of autoimmune or atopic illness
    History of chronic pain syndrome (fibromyalgia, chronic fatigue syndrome)
    Neurologic or neurodevelopmental disorders
    History of malignancy
    Tests Blood Stool
    Bacteria Treponema Enteric pathogen culture: Salmonella, Shigella, Campylobacter
    Helicobacter pylori EIAb)
    VRE
    Viruses Hepatitis A virus IgM Norovirus EIA or PCR
    Hepatitis surface antigen Rotavirus EIA
    Anti-hepatitis C virus
    HIV 1 and 2
    Parasites Entamoeba histolytica Ovum and parasite
    Strongyloides stercoralis Microsporidia
    Giardia fecal antigen/EIA
    Cryptosporidium EIA
    AFB for Isospora and Cyclospora
    Others Complete blood count Clostridium difficile test
    Liver function test Toxin PCR
    ESR and CRP
    Modality Strength Weakness
    Nasoenteric tube 1. No necessity for sedation 1. Discomfort associated with the administration
    2. Low cost 2. Necessity for radiologic confirmation
    3. Risk of vomiting and aspiration
    Upper endoscopy 1. Safely performed in patients with a high risk for colonoscopy complications 1. Same weaknesses as those of nasoenteric tube
    2. Procedure-related risk
    3. Necessity for sedation
    Capsule 1. Noninvasive 1. Large burden of the capsule
    2. More aesthetic appeal 2. Risk of vomiting and aspiration
    3. Cost- and time saving 3. Cost
    4. Convenience of administration
    Colonoscopy 1. Strong evidence of efficacy for rCDI 1. Procedure-related risk
    2. Useful for differential diagnosis 2. Necessity for sedation
    3. Necessity for technical expertise
    4. Additional cost
    Sigmoidoscopy 1. Can be preferred by patients 1. Procedure-related risk
    2. Inability to reach the right-sided colon
    Retention enema 1. Low cost 1. Difficult to retain in some cases
    2. Well tolerated 2. Inability to reach the right-sided colon
    3. No need for sedation and can be preferred by patients 3. Modality with the lowest efficacy
    4. Can be easily repeated
    Table 1. Suggested Exclusion Criteria for Potential Stool Donors with a Risk of Infection or Microbiome-Associated Disease

    HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome.

    Each institution can adopt different criteria.

    Table 2. Suggested Laboratory Tests for Potential Donors of Fecal Microbiota Transplantationa)

    AFB, acid-fast bacilli; CRP, C-reactive protein; EIA, enzyme immunoassay; ESR, erythrocyte sedimentation rate; HIV, human immunodeficiency virus; IgM, immunoglobulin M; PCR, polymerase chain reaction; VRE, vancomycin-resistant Enterococcus.

    The blood and stool tests should be completed within 1 month of donation, and the tests could be adopted differently depending on each institution and circumstance.

    The test for Helicobacter pylori is usually needed in the case of upper gastrointestinal delivery.

    Table 3. Analysis of Administration Modalities for Fecal Microbiota Transplantation

    rCDI, recurrent Clostridium difficile infection.

    Table 1.

    Table 2.

    Table 3.

    Clin Endosc : Clinical Endoscopy Twitter Facebook
    © Korean Society of Gastrointestinal Endoscopy.
    Close layer
    TOP